Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 11/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 11/20 | 0.39 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20311704 | 0.88 | EGFR (0.46) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL1585479 | 0.84 | EGFR (0.54) | EGFR | |
| SCHEMBL21756263 | 0.81 | EGFR (0.52) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL26043142 | 0.81 | EGFR (0.52) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL30127458 | 0.81 | EGFR (0.52) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL30926304 | 0.81 | EGFR (0.52) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL30126803 | 0.81 | EGFR (0.52) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL30457508 | 0.79 | EGFR (0.46) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL14659867 | 0.79 | IDO1 (0.46) | EGFRIDO1TDO2LPLLIPG | |
| SCHEMBL15743609 | 0.79 | EGFR (0.46) | EGFRIDO1TDO2LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4469452-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | Adorx therapeutics Limited (GB) | 2024-12-04 | — | — | EP | disclosed |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2024-03-14 | — | — | US | disclosed |
| CN-113166119-B | Substituted aryl compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-113166109-B | Aminopyridine compound and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-4259629-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | Adorx therapeutics Limited (GB) | 2023-10-18 | — | — | EP | disclosed |
| CN-116888119-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023144559-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | AdoRx Therapeutics Limited (GB) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023144559-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | AdoRx Therapeutics Limited (GB) | 2023-08-03 | — | — | WO | disclosed |
| CN-111377873-B | Aminopyrimidine compounds, their preparation and use | 四川科伦博泰生物医药股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2020011220-A1 | HETEROARYL DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2020-01-16 | — | — | WO | disclosed |
| CN-110684020-A | 2-aminopyrimidine derivatives, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-20190352278-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2019-11-21 | — | — | US | disclosed |
| EP-3569596-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2019-11-20 | — | — | EP | disclosed |
| WO-2018130184-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | 江苏恒瑞医药股份有限公司 | 2018-07-19 | — | — | WO | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637542-B2 | Kinase inhibitors and methods of use | INTELLIKINE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| WO-2009114870-A2 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352278-A1 | 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE | ADORA2B, ADORA2A, ADORA1 | EGFR 2673/4885IDO1 342/4885TDO2 418/4885 |
| US-20240083904-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | ADORA2A, ADORA1, ADORA3 | EGFR 636/4885IDO1 629/4885TDO2 1043/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | EGFR 592/4885IDO1 2929/4885TDO2 2971/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | EGFR 587/4885IDO1 796/4885TDO2 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.